The present invention relates to a transgenic mouse containing a latent oncogenic .beta.-catenin allele capable of spontaneous activation in vivo. The transgenic mouse is useful for the identification of compounds and immunotherapies for the prevention, treatment and/or cure of various forms of cancer associated with .beta.-catenin activation.